Search Videos and More
Symposium
Our Ambulatory Cell Therapies Clinic
Our growing outpatient cell therapies program enables many patients to receive stem cell transplant and CAR T-cell therapies without a lengthy hospital admission. Through this program, patients receive the same high-quality, comprehensive care – conditioning chemotherapy, cell infusion, and follow-up monitoring – in our Ambulatory Cell Therapies Clinic and return home or to nearby accommodations each day during their treatment period.
News
Dana-Farber Research News 03.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from February 1 - 15.
News
Dana-Farber Research News 02.15.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from January 16 - 31.
News
Dana-Farber, Gustave Roussy to Host Fifth Transatlantic Exchange in Oncology Focused on Cancer Drug Innovation
Dana-Farber Cancer Institute will host the Fifth Transatlantic Exchange in Oncology on Friday, March 27, 2026, bringing together leading cancer researchers and clinicians from the United States and Europe to explore transatlantic innovations in cancer drug research.
News
Making Breakthroughs in ALL From Youth to Adulthood
When Ann Carroll was diagnosed with cancer at age 28, her dream to get married and have a baby felt out of reach. Now, seven years later and cancer-free, she is living that dream with her husband and their 7-month-old son, Teddy.
News
Dana-Farber Launches Colorectal Cancer Screening Program in Central Asia
Dana-Farber Cancer Institute's Center for Global Health launched the first colorectal cancer screening program in Central Asia this week, partnering with Uzbekistan’s Ministry of Health and National Cancer Center to pilot a sustainable, early detection model that could be scaled across the region.
News
Dana-Farber Research Helps Drive FDA Label Update for Primary CNS Lymphoma
Change removes prior exclusion and may expand access to CAR T-cell therapy for eligible relapsed or refractory patients
News
Three Dana-Farber Cancer Institute scientific leaders elected as Fellows of the American Association for Cancer Research (AACR) Academy Class of 2026
Dr. Alice Shaw, Dr. Kimberly Stegmaier and Dr. Matthew Vander Heiden have been elected as Fellows of the American Association for Cancer Research (AACR) Academy Class of 2026.
News
Taming Chronic Inflammation
Dana-Farber researchers explore how lifestyle choices may help reduce cancer risk and improve outcomes
News
Dana-Farber Research News 02.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 16 - 31.
News
Ten Cancer-Related Breakthroughs Giving Us Hope in 2026
Cancer treatment has evolved dramatically in the first quarter of this century, but there is still much more to do to improve the lives of people with cancer.
News
More Than 145 Dana-Farber Affiliated Faculty Named as 2026 Top Doctors™ in Boston Magazine
Boston magazine has named more than 145 physicians affiliated with Dana-Farber Cancer Institute to its annual "Top Doctors" guide. Drawing from a Castle Connolly Medical Ltd. physician database, the Boston magazine Top Doctors™ list draws from hundreds of Boston-area physicians in many medical specialties